Abstract
BACKGROUND Permanent cardiac pacemakers have historically been considered a contraindication to magnetic resonance imaging (MRI).
OBJECTIVE The purpose of the ProMRI Phase B Study, a multicenter, prospective, single-arm, nonrandomized study, was to evaluate the clinical safety of the Biotronik ProMRI pacemaker system in patients undergoing thoracic spine and cardiac MRI.
METHODS The ProMRI Phase B study enrolled 245 patients with stable baseline pacing indices implanted with an Entovis pacemaker (DR-T or SR-T) and Setrox 53-cm and/or 60-cm lead(s). Device interrogation was performed at enrollment, pre- and post- MRI scan, and 1 and 3 months post-MRI. End-points were (1) freedom from MRI- and pacing system–related serious adverse device effects through 1 month post-MRI; (2) freedom from atrial and ventricular MRI-induced pacing threshold increase (˂0.5 V); and (3) freedom from P- and R-wave amplitude attenuation (˂50%), or P wave ˂1.5 mV, or R wave ˂5.0 mV at 1 month post-MRI.
RESULTS In total, 216 patients completed the MRI and 1-month post-MRI follow-up. One adverse event possibly related to the implanted system and the MRI procedure occurred, resulting in a serious adverse device effect–free rate of 99.6% (220/221; P ˂.0001. Freedom from atrial and ventricular pacing threshold increase was 100% (194/194, P ˂.001) and 100% (206/206,P ˂.001) respectively. Freedom from P- and R-wave amplitude attenuation was 98.2% (167/170, P ˂.001) and 100% (188/188,P ˂.001) respectively.
CONCLUSION The results of the ProMRI Phase B study demonstrate the clinical safety and efficacy of the ProMRI pacemaker system in patients subjected to thoracic spine and cardiac MRI conditions.